Johnson & Johnsonvs.Merck & Co.
JNJ vs MRK · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Johnson & Johnson is about 1.9× larger than Merck & Co. by market cap; Johnson & Johnson trades at the lower P/E (29.9 vs 103.9); year to date, Merck & Co. leads (+43.1% vs +31.9%).
Side by side
| JNJ | MRK | |
|---|---|---|
| Market cap | $630B | $330B |
| Price | $273.14 | $156.45 |
| Today | +0.0% | +3.8% |
| Return YTD | +31.9% | +43.1% |
| Return 1Y | +52.3% | +72.4% |
| P/E | 29.9 | 103.9 |
| P/S | 6.4 | 5.0 |
| P/B | 7.4 | 7.2 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Johnson & JohnsonJNJ
Two businesses under one name: Innovative Medicine, which covers immunology and oncology drugs, and MedTech, which makes medical devices and surgical equipment.
Full JNJ profile →Merck & Co.MRK
Keytruda is the centre of the oncology business, which sits next to a substantial vaccines portfolio. Animal health forms a third division.
Full MRK profile →More JNJ & MRK comparisons
Other head-to-heads in the Big pharma segment.